We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) has agreed to pay $175 million to settle a class action lawsuit alleging the company violated antitrust laws in obtaining and enforcing its patent for the nonsteroidal anti-inflammatory drug Relafen (nabumetone) to the injury of drug wholesalers and other direct purchasers.
Mylan has been sued for patent infringement by Japanese drugmaker Eisai over its bid to market a version of Eisai’s gastrointestinal treatment Aciphex (rabeprazole sodium).
A federal district court on Feb. 4 vacated a preliminary injunction that GlaxoSmithKline (GSK) had sought against Eon Labs over its generic version of GSK’s antidepressant Wellbutrin SR (bupropion HCl) 100-mg tablets.
The FDA will appeal a recent district court ruling that overturned the agency’s decision to grant shared 180-day exclusivity to several generic firms seeking to market a version of GlaxoSmith
Cost-containment concerns at HHS and an increase in fraud prosecutions by U.S. attorneys are driving a growing investigatory focus on drugmakers’ off-label promotions and their alleged connection to false Medicare and Medicaid claims, according to healthcare and First Amendment legal experts.
The FDA yesterday said it will appeal a recent district court ruling that overturned the agency’s decision to grant shared 180-day exclusivity to several generic firms seeking to market a version of GlaxoSmithKline’s depression drug Paxil (paroxetine HCl).
In a procedural move, a federal district court yesterday pulled a preliminary injunction that GlaxoSmithKline (GSK) had sought against Eon Labs over its generic version of GSK’s antidepressant Wellbutrin SR (bupropion HCl) 100-mg tablets.
Japanese drugmaker Eisai has filed a patent infringement lawsuit against generic firm Mylan over its bid to market a version of Eisai’s gastrointestinal treatment Aciphex (rabeprazole sodium).
A federal appeals court yesterday upheld a lower court ruling that found generic firm Impax did not infringe on a patent covering GlaxoSmithKline’s (GSK’s) top selling antidepressant Wellbutrin SR (bupropion HCl) extended-release tablets.